Works matching AU Zhang, Qingyuan

Results: 214
    1
    2
    3
    4

    Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial

    Published in:
    EJHaem, 2022, v. 3, n. 4, p. 1154, doi. 10.1002/jha2.517
    By:
    • Zhu, Jun;
    • Hong, Xiaonan;
    • Song, Yu Qin;
    • Hodkinson, Brendan;
    • Balasubramanian, Sriram;
    • Wang, Songbai;
    • Zhang, Qingyuan;
    • Shi, Yuankai;
    • Huang, Huiqiang;
    • Zhang, Huilai;
    • Zhu, Yan;
    • Shreeve, Stephen Martin;
    • Sun, Steven;
    • Wang, Ze;
    • Wang, Xiaocan;
    • Fan, Yue;
    • Wilson, Wyndham;
    • Vermeulen, Jessica
    Publication type:
    Article
    5
    6
    7
    8

    Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-58647-z
    By:
    • Wang, Jiayu;
    • Zhang, Qingyuan;
    • Li, Huiping;
    • Tong, Zhongsheng;
    • Ouyang, Quchang;
    • Li, Huihui;
    • Teng, Yuee;
    • Wang, Biyun;
    • Sun, Tao;
    • Wang, Jingfen;
    • Li, Wei;
    • Niu, Zhaofeng;
    • Li, Hongsheng;
    • Gong, Chang;
    • Wang, Shu;
    • Wang, Xinshuai;
    • Wu, Xinhong;
    • Liu, Ning;
    • Yu, Guohua;
    • Liu, Fei
    Publication type:
    Article
    9

    Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-56096-2
    By:
    • Xu, Binghe;
    • Zhang, Qingyuan;
    • Luo, Yang;
    • Tong, Zhongsheng;
    • Sun, Tao;
    • Shan, Changping;
    • Liu, Xinlan;
    • Yao, Yumin;
    • Zhao, Bing;
    • Wang, Shusen;
    • Zeng, Xiaohua;
    • Hu, Changlu;
    • Yan, Xi;
    • Wang, Xiaojia;
    • Jia, Hongyan;
    • Chen, Zhendong;
    • Qiu, Fuming;
    • Wu, Xinhong;
    • Zhang, Deyong;
    • Li, Tong
    Publication type:
    Article
    10
    11
    12
    13

    Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial.

    Published in:
    2021
    By:
    • Song, Yuqin;
    • Zhou, Hui;
    • Zhang, Huilai;
    • Liu, Wei;
    • Shuang, Yuerong;
    • Zhou, Keshu;
    • Lv, Fangfang;
    • Xu, Hao;
    • Zhou, Jianfeng;
    • Li, Wei;
    • Wang, Huaqing;
    • Zhang, Hongyu;
    • Huang, Haiwen;
    • Zhang, Qingyuan;
    • Xu, Wei;
    • Ge, Zheng;
    • Xiang, Ying;
    • Wang, Shuye;
    • Gao, Da;
    • Yang, Shun'e
    Publication type:
    journal article
    14

    Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study.

    Published in:
    BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-13736-6
    By:
    • Shi, Yuankai;
    • Wang, Xinshuai;
    • Pei, Zhidong;
    • Shi, Huaqiu;
    • Zhang, Yanjun;
    • Yi, Tienan;
    • Mei, Jiazhuan;
    • Guo, Yanzhen;
    • Dong, Youhong;
    • Ma, Tianjiang;
    • Zhang, Qingyuan;
    • Jia, Xiaojing;
    • Zhu, Zhengqiu;
    • Xu, Shen;
    • Liu, Yanyan;
    • Niu, Hongrui;
    • Jiang, Weimei;
    • Jiang, Xiaodong;
    • Zhou, Shengyu;
    • Sun, Li
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29

    Toll-like receptors and prostate cancer.

    Published in:
    Frontiers in Immunology, 2014, v. 5, p. 1, doi. 10.3389/fimmu.2014.00352
    By:
    • Shu Zhao;
    • Yifan Zhang;
    • Qingyuan Zhang;
    • Fen Wang;
    • Dekai Zhang
    Publication type:
    Article
    30

    Toll-like Receptors and Prostate Cancer.

    Published in:
    Frontiers in Immunology, 2014, v. 5, p. 1, doi. 10.3389/fimmu.2014.00352
    By:
    • Shu Zhao;
    • Yifan Zhang;
    • Qingyuan Zhang;
    • Fen Wang;
    • Dekai Zhang
    Publication type:
    Article
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46

    P1099: A PHASE II, MULTICENTER, SINGLE‐ARM STUDY OF PARSACLISIB, A PI3KΔ INHIBITOR, IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN CHINA: UPDATED RESULTS FROM THE STUDY.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000971292.12638.60
    By:
    • Zheng, Zhong;
    • Zhang, Huilai;
    • Zhou, Keshu;
    • Zhou, Hui;
    • Zhang, Li;
    • Li, Caixia;
    • Zhou, Min;
    • Qian, Wenbin;
    • Li, Zhiming;
    • Zhang, Qingyuan;
    • Cheng, Ying;
    • Peng, Liu;
    • Li, Zhenyu;
    • Su, Liping;
    • Li, Fei;
    • Sun, Xiuhua;
    • Wang, Jingwen;
    • Gao, Yuhuan;
    • Zhao, Xielan;
    • Li, Kunyan
    Publication type:
    Article
    47
    48
    49
    50